WO2006135641A2 - PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE - Google Patents

PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE Download PDF

Info

Publication number
WO2006135641A2
WO2006135641A2 PCT/US2006/022155 US2006022155W WO2006135641A2 WO 2006135641 A2 WO2006135641 A2 WO 2006135641A2 US 2006022155 W US2006022155 W US 2006022155W WO 2006135641 A2 WO2006135641 A2 WO 2006135641A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
phenyl
formula
compound
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/022155
Other languages
French (fr)
Other versions
WO2006135641A3 (en
Inventor
Joseph Mckenna
Wen-Chung Shieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/915,671 priority Critical patent/US8124763B2/en
Priority to JP2008515881A priority patent/JP5118024B2/en
Priority to CN2006800184259A priority patent/CN101184748B/en
Priority to DE602006018156T priority patent/DE602006018156D1/en
Priority to MX2007015423A priority patent/MX2007015423A/en
Priority to SI200630903T priority patent/SI1924574T1/en
Priority to CA2610105A priority patent/CA2610105C/en
Priority to KR1020137025659A priority patent/KR101514593B1/en
Priority to AT06772448T priority patent/ATE487709T1/en
Priority to HK08108277.9A priority patent/HK1117524B/en
Priority to AU2006258051A priority patent/AU2006258051B2/en
Priority to EP06772448A priority patent/EP1924574B1/en
Priority to BRPI0611663-9A priority patent/BRPI0611663A2/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to DK06772448.4T priority patent/DK1924574T3/en
Priority to PL06772448T priority patent/PL1924574T3/en
Priority to NZ563740A priority patent/NZ563740A/en
Publication of WO2006135641A2 publication Critical patent/WO2006135641A2/en
Publication of WO2006135641A3 publication Critical patent/WO2006135641A3/en
Priority to IL187421A priority patent/IL187421A/en
Priority to TNP2007000463A priority patent/TNSN07463A1/en
Priority to EGNA2007001382 priority patent/EG25039A/en
Anticipated expiration legal-status Critical
Priority to NO20080157A priority patent/NO340743B1/en
Priority to US13/353,434 priority patent/US8946416B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention provides a new method of making compounds of formula (I):
  • R1 is mono- or polysubstituted aryl
  • R2 is hydrogen, lower alkyl or aryl
  • R4 is hydrogen, lower alkyl, or halogen.
  • a preferred compound of formula (I) is 4-methyl-3-[[4-(3-pyridinyI)-2-pyrimidinyl]amino]- ⁇ /-[5- (4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide (Ia).
  • compounds of formula (I) have been shown to inhibit one or more tyrosine kinases, such as c-Abl, Bcr-Abl, the receptor tyrosine kinases PDGF-R 1 Flt3, VEGF-R, EGF-R and c-Kit.
  • compounds of formula (I) can be used for the treatment of certain neoplastic diseases, such as leukemia.
  • the present invention overcomes the problems encountered in the previous synthesis described in Scheme 1 and typically resulted in an increased overall yield from 54-86%.
  • the present invention provides a new method of making compounds of formula (I):
  • R1 is substituted or unsubstituted aryl
  • R2 is hydrogen, lower alky or aryl
  • R4 is hydrogen, lower alkyl or halogen
  • R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
  • R1 is substituted or unsubstituted aryl
  • R2 is hydrogen, lower alky or aryl
  • R4 is hydrogen, lower alkyl or halogen
  • R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
  • Direct condensation of ester (II) with aniline (IV) can be catalyzed by a strong base such as potassium tert-butoxide to make compounds of formula (I) in good yield and high purity without any chromatography or recrystallization purification.
  • a strong base such as potassium tert-butoxide
  • Other bases such as metal hydride, bulkyl alkyl lithium, metal alkoxide, metal £>/s(trimethylsilyl) amide or lithium dialkylamide, can also be used.
  • the metal can be lithium, sodium or potassium.
  • the process is carried out at temperature between -5O 0 C to 5O 0 C in an organic solvent of tetrahydrofuran, dimethylformamide, toluene or ⁇ /-methylpyrrolidinone.
  • the process comprises the following reaction:
  • R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
  • the compound of formula (IVa) can be prepared using processes disclosed in patent applications U.S. SN 60/688,920 and SN 60/688,976, both entitled “Process for the Synthesis of Organic Compounds", which were filed concurrently herewith. The disclosures of those applications are incorporated herein by reference. In the most preferred embodiment, the process comprises the following reaction:
  • Lower alkyl comprises 1 -6 carbon atoms, and is linear or branched; preferred lower alkyl moieties are butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Particularly preferred lower alkyl moieties are methyl, ethyl, /7-propyl or te/f-butyl.
  • aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical.
  • aryl is an aromatic radical having 6-14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, wherein the substituents are heterocyclyl groups comprising one, two, three ring nitrogen atoms, one oxygen atom or one sulfur atom; other substituents on aryl include disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, etherified hydroxy, esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, carbamoyl
  • aryl is phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group consisting of halogen, especially fluorine, chlorine or bromine; hydroxy etherified by lower alkyl, e.g., by methyl, by halogen-lower alkyl, e.g., trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g., methylenedioxy, lower alkyl, e.g., methyl or propyl; halogen-lower alkyl, e.g., trifluoromethyl; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxy-2-propyl; lower alkoxy-lower alkyl; e.g., methoxymethyl or 2-methoxyethyl;
  • Halogen is fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
  • Example 1 The following examples more particularly illustrate the present invention, but do not limit the invention in any way.
  • Example 1 The following examples more particularly illustrate the present invention, but do not limit the invention in any way.
  • a solution of 15% aqueous sodium chloride (500 mL) is added to the mixture, maintaining temperature below 15°C.
  • Product is extracted into isopropyl acetate (500 mL) and washed in sequence with 15% aqueous sodium chloride solution (500 mL) and water (500 mL).
  • the organic phase is distilled under atmospheric pressure at an internal temperature of 75-85°C until the residual volume is about 200 mL.
  • the resulting suspension is cooled to 70 ⁇ 5°C and charged with ethanol (250 mL) and water (30 mL).
  • the mixture is heated to reflux (78 0 C) for 1 hour and then cooled to -1O 0 C to -15°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention provides a new method of making compounds of formula (I): wherein R1 is mono- or polysubstituted aryl; R2 is hydrogen, lower alkyl or aryl; and R4 is hydrogen, lower alkyl or halogen.

Description

PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS
Background of the Invention
The present invention provides a new method of making compounds of formula (I):
Figure imgf000002_0001
wherein
R1 is mono- or polysubstituted aryl; R2 is hydrogen, lower alkyl or aryl; and R4 is hydrogen, lower alkyl, or halogen.
Compounds of formula (I) have been disclosed in W. Breitenstein et al., WO 04/005281 which published on January 15, 2004, the disclosure of which is incorporated by reference. A preferred compound of formula (I) is 4-methyl-3-[[4-(3-pyridinyI)-2-pyrimidinyl]amino]-Λ/-[5- (4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide (Ia). Compounds of formula (I) have been shown to inhibit one or more tyrosine kinases, such as c-Abl, Bcr-Abl, the receptor tyrosine kinases PDGF-R1 Flt3, VEGF-R, EGF-R and c-Kit. As such, compounds of formula (I) can be used for the treatment of certain neoplastic diseases, such as leukemia.
Previous synthesis of compounds of formula (I), and specifically (Ia), involves a hydrolysis of an ethyl ester to a carboxylic acid, which is then reacted with an aniline, and employing diethylcyanophosphonate as a coupling agent as shown in Scheme 1. Scheme 1
Figure imgf000003_0001
(Ha) (Ilia)
Figure imgf000003_0002
diethylcyanophosphonate
Figure imgf000003_0003
(Ia)
This process gives low and inconsistent yields. Furthermore, diethylcyanophosphonate is an expensive reagent. Thus, there is a need for an alternate process that is cheaper, consistent, efficient, and produces compounds (I) in high yields.
It is an object of this invention to provide for an alternative process to make compounds of formula (I) efficiently with high and consistent yields.
It is a further object of this invention to make compounds of formula (I) from lower cost reagents.
It is a still further object of this invention to provide for a process to make compounds of formula (I) utilizing safer reagents.
The present invention overcomes the problems encountered in the previous synthesis described in Scheme 1 and typically resulted in an increased overall yield from 54-86%. Summary of the Invention
The present invention provides a new method of making compounds of formula (I):
Figure imgf000004_0001
comprising the following reaction:
Scheme 2
Figure imgf000004_0002
(H) (0
wherein
R1 is substituted or unsubstituted aryl;
R2 is hydrogen, lower alky or aryl;
R4 is hydrogen, lower alkyl or halogen; and
R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
Direct condensation of ester (II) with aniline (IV) is catalyzed by a base, such as potassium tert-butoxide to make compounds of formula (I). The process is carried out at temperature between -500C to 5O0C in an organic solvent of tetrahydrofuran, dimethylformamide, toluene or Λ/-methylpyrrolidinone. Detailed Description of the Invention
The general reaction scheme of the invention can be illustrated as follows:
Scheme 2
Figure imgf000005_0001
(") (0
wherein
R1 is substituted or unsubstituted aryl;
R2 is hydrogen, lower alky or aryl;
R4 is hydrogen, lower alkyl or halogen; and
R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
Direct condensation of ester (II) with aniline (IV) can be catalyzed by a strong base such as potassium tert-butoxide to make compounds of formula (I) in good yield and high purity without any chromatography or recrystallization purification. Other bases, such as metal hydride, bulkyl alkyl lithium, metal alkoxide, metal £>/s(trimethylsilyl) amide or lithium dialkylamide, can also be used. The metal can be lithium, sodium or potassium. The process is carried out at temperature between -5O0C to 5O0C in an organic solvent of tetrahydrofuran, dimethylformamide, toluene or Λ/-methylpyrrolidinone.
In a preferred embodiment, the process comprises the following reaction:
Scheme 3
Figure imgf000006_0001
(lib) (IVa)
Figure imgf000006_0002
(Ia) wherein R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl.
The compound of formula (IVa) can be prepared using processes disclosed in patent applications U.S. SN 60/688,920 and SN 60/688,976, both entitled "Process for the Synthesis of Organic Compounds", which were filed concurrently herewith. The disclosures of those applications are incorporated herein by reference. In the most preferred embodiment, the process comprises the following reaction:
Scheme 4
Figure imgf000007_0001
(lie) (IVa)
Figure imgf000007_0002
(Ia)
As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.
Lower alkyl comprises 1 -6 carbon atoms, and is linear or branched; preferred lower alkyl moieties are butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Particularly preferred lower alkyl moieties are methyl, ethyl, /7-propyl or te/f-butyl.
An aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical. In a preferred embodiment, aryl is an aromatic radical having 6-14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, wherein the substituents are heterocyclyl groups comprising one, two, three ring nitrogen atoms, one oxygen atom or one sulfur atom; other substituents on aryl include disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, etherified hydroxy, esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, Λ/-mono- or Λ/,Λ/-disubstituted carbamoyl, amidino, guanidino, ureido, mercapto, sulfo, lower alkylthio, phenylthio, phenyl- lower alkylthio, lower alkylphenylthio, lower alkylsulfinyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, lower alkylphenylsulfinyl, lower alkylsulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, lower alkylphenylsulfonyl, halogen-lower alkyl mercapto, halogen-lower alkylsulfonyl, such as especially trifluoromethanesulfonyl, heterocyclyl, a mono- or bicyclic heteroaryl group or lower alkylene dioxy bound at adjacent C-atoms of the ring, such as methylene dioxy. According to a preferred embodiment, aryl is phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group consisting of halogen, especially fluorine, chlorine or bromine; hydroxy etherified by lower alkyl, e.g., by methyl, by halogen-lower alkyl, e.g., trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g., methylenedioxy, lower alkyl, e.g., methyl or propyl; halogen-lower alkyl, e.g., trifluoromethyl; hydroxy-lower alkyl, e.g., hydroxymethyl or 2-hydroxy-2-propyl; lower alkoxy-lower alkyl; e.g., methoxymethyl or 2-methoxyethyl; lower alkoxycarbonyl-lower alkyl, e.g., methoxy- carbonyl methyl; lower alkynyl, such as 1-propynyl; esterified carboxy, especially lower alkoxycarbonyl, e.g., methoxycarbonyl, n-propoxy carbonyl or isopropoxy carbonyl; Λ/-mono- substituted carbamoyl, in particular, carbamoyl monosubstituted by lower alkyl, e.g., methyl, n-propyl or isopropyl; di-lower alkylamino, e.g., dimethylamino or diethylamino; lower alkylene-amino, e.g., pyrrolidino or piperidino; lower oxaalkylene-amino, e.g., morpholino, lower azaalkylene-amino, e.g., piperazino, acylamino, e.g., acetylamino or benzoylamino; lower alkylsulfonyl, e.g., methylsulfonyl; sulfamoyl; and phenylsulfonyl.
Halogen is fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
The following examples more particularly illustrate the present invention, but do not limit the invention in any way. Example 1
Synthesis of compound of formula (Ia)
Figure imgf000009_0001
(Hc) (IVa)
Figure imgf000009_0002
(Ia)
To a 1 -L flask, equipped with a mechanical stirrer, temperature sensor, reflux condenser, addition funnel and nitrogen inlet-outlet under a nitrogen atmosphere at 23°C is charged with compounds (lie) (16 g), (IVa) (12 g) and THF (300 mL). The mixture is stirred for 15 minutes at 23°C and cooled to -2O0C to -15°C. A solution of 1 M potassium f-butoxide in THF (275 mL) is added at -2O0C to -100C. After the addition, the mixture is warmed to 18-23°C. When the reaction is complete according to HPLC, the mixture is cooled to 5°C. A solution of 15% aqueous sodium chloride (500 mL) is added to the mixture, maintaining temperature below 15°C. Product is extracted into isopropyl acetate (500 mL) and washed in sequence with 15% aqueous sodium chloride solution (500 mL) and water (500 mL). The organic phase is distilled under atmospheric pressure at an internal temperature of 75-85°C until the residual volume is about 200 mL. The resulting suspension is cooled to 70 ± 5°C and charged with ethanol (250 mL) and water (30 mL). The mixture is heated to reflux (780C) for 1 hour and then cooled to -1O0C to -15°C. The suspension is stirred for an additional 30 minutes at -1O0C to -15°C. Any solid is collected by filtration, rinsed with cold (50C) ethanol (85 ml_) and dried under vacuum (10-20 torr) at 55-6O0C with a nitrogen bleed (8-16 hours) to obtain AMN107 (17.4 g, 67% yield) as a white solid.
1H NMR 300 MHz, DMSOd6), δ 10.5 (s, 1 H), 9.15 (s, 1 H), 9.05 (S, 1 H), 8.60 (s, 1 H), 8.45 (d, 1 H), 8.35 (d, 1 H), 8.22 (d, 2H), 8.10 (d, 2H)1 7.65 (m, 2H), 7.45 (m, 4H), 2.25 (s, 3H), 2.05 (s, 3H).

Claims

What is claimed is:
1. A process for the preparation of compounds of formula (I)
Figure imgf000011_0001
comprising reacting the compound:
Figure imgf000011_0002
with R1-NH-R2, wherein
R1 is substituted or unsubstituted aryl;
R2 is hydrogen, lower alky or aryl;
R4 is hydrogen, lower alkyl or halogen; and
R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl, and wherein the process is catalyzed by a base in an organic solvent.
2. A process for the preparation of a compound of the formula (Ia)
Figure imgf000012_0001
comprising reacting the compound:
Figure imgf000012_0002
wherein R3 is lower alkyl, phenyl, phenyl-lower alkyl or substituted phenyl, with the compound 5-(4-methyI-1 H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine of the structure (IVa):
Figure imgf000012_0003
(IVa)
and wherein the process is catalyzed by a base in an organic solvent.
3. A process for the preparation of a compound of the formula (Ia)
Figure imgf000013_0001
comprising reacting the compound:
Figure imgf000013_0002
with 5-(4-methyI-1 H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine (IVa) wherein the process is catalyzed by a base in an organic solvent.
4. The process of any one of Claims 1 -3, wherein the base is selected from the group consisting of metal hydride, bulky alkyl lithium, metal alkoxide, metal £>/s(trimethylsilyl)amide and lithium dialkylamide.
5. The process of Claim 4, wherein the metal is selected from the group consisting of lithium, sodium and potassium.
6. The process of Claim 4, wherein the base is potassium tert-butoxide.
7. The process of any one of Claims 1-3, wherein the organic solvent is selected from the group of tetrahydrofuran, dimethylformamide, toluene and /V-methylpyrrolidone.
PCT/US2006/022155 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE Ceased WO2006135641A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
BRPI0611663-9A BRPI0611663A2 (en) 2005-06-09 2006-06-07 process for synthesis of organic compounds
CN2006800184259A CN101184748B (en) 2005-06-09 2006-06-07 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
DE602006018156T DE602006018156D1 (en) 2005-06-09 2006-06-07 PROCESS FOR SYNTHESIS OF 5- (METHYL-1H-IMIDAZOLE-1-YL) -3- (TRIFLUOROMETHYL) BENZOLAMINE
MX2007015423A MX2007015423A (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE.
SI200630903T SI1924574T1 (en) 2005-06-09 2006-06-07 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
CA2610105A CA2610105C (en) 2005-06-09 2006-06-07 Process for the synthesis of organic compounds
KR1020137025659A KR101514593B1 (en) 2005-06-09 2006-06-07 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
AT06772448T ATE487709T1 (en) 2005-06-09 2006-06-07 METHOD FOR SYNTHESIS OF 5-(METHYL-1H-IMIDAZOLE-1-YL)-3-(TRIFLUORMETHYL)BENZOLAMINE
JP2008515881A JP5118024B2 (en) 2005-06-09 2006-06-07 Synthesis method of organic compounds
AU2006258051A AU2006258051B2 (en) 2005-06-09 2006-06-07 Process for the synthesis of 5- (methyl-1H-imidazol-1-yl) -3- (tri fluorome th yl) -benzeneamine
EP06772448A EP1924574B1 (en) 2005-06-09 2006-06-07 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
US11/915,671 US8124763B2 (en) 2005-06-09 2006-06-07 Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
DK06772448.4T DK1924574T3 (en) 2005-06-09 2006-06-07 Process for the Synthesis of 5- (Methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) -benzenamine
HK08108277.9A HK1117524B (en) 2005-06-09 2006-06-07 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
PL06772448T PL1924574T3 (en) 2005-06-09 2006-06-07 Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
NZ563740A NZ563740A (en) 2005-06-09 2006-06-07 Process for the synthesis of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide
IL187421A IL187421A (en) 2005-06-09 2007-11-15 Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluoromethyl)-benzeneamine
TNP2007000463A TNSN07463A1 (en) 2005-06-09 2007-12-07 Process for the synthesis of organic compounds
EGNA2007001382 EG25039A (en) 2005-06-09 2007-12-09 Process for preparation of compounds used for inhibition of one or more tyrosine kinases.
NO20080157A NO340743B1 (en) 2005-06-09 2008-01-09 Process for the synthesis of organic compounds
US13/353,434 US8946416B2 (en) 2005-06-09 2012-01-19 Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68897705P 2005-06-09 2005-06-09
US60/688,977 2005-06-09
US70559005P 2005-08-04 2005-08-04
US60/705,590 2005-08-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/915,671 A-371-Of-International US8124763B2 (en) 2005-06-09 2006-06-07 Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
US13/353,434 Division US8946416B2 (en) 2005-06-09 2012-01-19 Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine

Publications (2)

Publication Number Publication Date
WO2006135641A2 true WO2006135641A2 (en) 2006-12-21
WO2006135641A3 WO2006135641A3 (en) 2007-03-29

Family

ID=37091153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/022155 Ceased WO2006135641A2 (en) 2005-06-09 2006-06-07 PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE

Country Status (31)

Country Link
US (2) US8124763B2 (en)
EP (1) EP1924574B1 (en)
JP (1) JP5118024B2 (en)
KR (3) KR101514593B1 (en)
AR (1) AR053890A1 (en)
AT (1) ATE487709T1 (en)
AU (1) AU2006258051B2 (en)
BR (1) BRPI0611663A2 (en)
CA (1) CA2610105C (en)
CY (1) CY1111428T1 (en)
DE (1) DE602006018156D1 (en)
DK (1) DK1924574T3 (en)
EC (1) ECSP077982A (en)
EG (1) EG25039A (en)
GT (1) GT200600217A (en)
IL (1) IL187421A (en)
JO (1) JO2636B1 (en)
MA (1) MA29599B1 (en)
MX (1) MX2007015423A (en)
MY (1) MY147436A (en)
NO (1) NO340743B1 (en)
NZ (1) NZ563740A (en)
PE (1) PE20070015A1 (en)
PL (1) PL1924574T3 (en)
PT (1) PT1924574E (en)
RU (1) RU2444520C2 (en)
SA (1) SA06270147B1 (en)
SI (1) SI1924574T1 (en)
TN (1) TNSN07463A1 (en)
TW (1) TWI430999B (en)
WO (1) WO2006135641A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
WO2010009402A3 (en) * 2008-07-17 2010-08-26 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
US8227477B2 (en) 2008-11-05 2012-07-24 Greta Sterimbaum Nilotinib HCl crystalline forms
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2012174082A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061029B2 (en) 2009-11-17 2015-06-23 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
US10392351B2 (en) 2014-01-07 2019-08-27 Suzhou Lixin Pharmaceutical Co., Ltd. Method for preparing nilotinib intermediate
JP2020007240A (en) * 2018-07-04 2020-01-16 住友化学株式会社 Method for producing benzamide compound
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (en) * 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
EP2691539B1 (en) 2011-03-31 2018-04-25 The Procter and Gamble Company Methods for identifying and evaluating skin-active agents effective for treating dandruff
WO2013184908A2 (en) 2012-06-06 2013-12-12 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
TWI831259B (en) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 Capsule containing dasatinib lauryl sulfate composition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136082A (en) * 1990-08-03 1992-08-04 Himont Incorporated Process for preparing organic esters and amides and catalyst system therefor
CA2151491A1 (en) 1992-12-24 1994-07-07 Robert J. Kaufman Fluorocarbon emulsions
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
AR013261A1 (en) 1997-08-01 2000-12-13 Smithkline Beecham Corp PHARMACEUTICAL FORMULATIONS FOR CAMPTOTECINE ANALOGS IN A GELATIN CAPSULE
US20030059465A1 (en) 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1044977B1 (en) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
IT1306129B1 (en) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
DE19926056B4 (en) 1999-06-08 2004-03-25 Gkss-Forschungszentrum Geesthacht Gmbh Device for analyzing atomic and / or molecular elements using wavelength-dispersive, X-ray spectrometric devices
GB9918885D0 (en) 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20040009229A1 (en) 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
US20020150615A1 (en) 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6629598B2 (en) 2001-08-10 2003-10-07 Vinod K. Narula Flexible ribbed splint system
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CN1592607A (en) 2001-10-15 2005-03-09 克里蒂泰克公司 Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
JP2003267891A (en) 2002-03-13 2003-09-25 Mitsubishi-Kagaku Foods Corp W / O / W emulsion formulation
US7202367B2 (en) 2002-05-31 2007-04-10 Rhodia Chimie Process for arylating or vinylating or alkynating a nucleophilic compound
CZ294371B6 (en) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilized pharmaceutical composition based on polyoxyethylated castor oil and process for preparing thereof
EP1393719A1 (en) 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4426749B2 (en) 2002-07-11 2010-03-03 株式会社産学連携機構九州 O / W emulsion formulation
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
JP2006199590A (en) 2003-09-04 2006-08-03 Nano Career Kk Composition containing nanoparticle containing water-soluble basic medicine encapsulated therein
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
EP1694242B1 (en) 2003-12-17 2014-04-16 Bionumerik Pharmaceuticals, Inc. Process for making pharmaceutical 7-(2-trimethylsilylethyl) camptothecin formulations
GT200500310A (en) 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067929B2 (en) 2007-06-04 2015-06-30 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US8586600B2 (en) 2007-06-04 2013-11-19 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2305667A2 (en) 2008-07-17 2011-04-06 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
EP2305667A3 (en) * 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
WO2010009402A3 (en) * 2008-07-17 2010-08-26 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
US8227477B2 (en) 2008-11-05 2012-07-24 Greta Sterimbaum Nilotinib HCl crystalline forms
US8592442B2 (en) 2008-11-05 2013-11-26 Teva Pharmaceutical Industries Ltd. Nilotinib HCl crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
US9061029B2 (en) 2009-11-17 2015-06-23 Novartis Ag Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
WO2012174082A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US10392351B2 (en) 2014-01-07 2019-08-27 Suzhou Lixin Pharmaceutical Co., Ltd. Method for preparing nilotinib intermediate
EP3095782A1 (en) 2015-05-18 2016-11-23 Esteve Química, S.A. New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
US12194432B2 (en) 2018-02-05 2025-01-14 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
JP2020007240A (en) * 2018-07-04 2020-01-16 住友化学株式会社 Method for producing benzamide compound

Also Published As

Publication number Publication date
AR053890A1 (en) 2007-05-23
SA06270147B1 (en) 2009-12-22
CA2610105C (en) 2014-03-25
JP2008545786A (en) 2008-12-18
US20080188656A1 (en) 2008-08-07
TWI430999B (en) 2014-03-21
PT1924574E (en) 2011-02-08
MY147436A (en) 2012-12-14
CA2610105A1 (en) 2006-12-21
US8946416B2 (en) 2015-02-03
EG25039A (en) 2011-07-06
SI1924574T1 (en) 2011-02-28
AU2006258051A1 (en) 2006-12-21
KR20080022093A (en) 2008-03-10
BRPI0611663A2 (en) 2010-09-28
RU2007148231A (en) 2009-07-20
ATE487709T1 (en) 2010-11-15
PL1924574T3 (en) 2011-04-29
KR101216249B1 (en) 2012-12-28
DE602006018156D1 (en) 2010-12-23
MA29599B1 (en) 2008-07-01
CY1111428T1 (en) 2015-08-05
IL187421A (en) 2011-11-30
EP1924574B1 (en) 2010-11-10
DK1924574T3 (en) 2011-02-14
EP1924574A2 (en) 2008-05-28
US20120116081A1 (en) 2012-05-10
KR101514593B1 (en) 2015-04-22
ECSP077982A (en) 2008-01-23
GT200600217A (en) 2007-03-28
AU2006258051B2 (en) 2010-09-09
NO20080157L (en) 2008-01-09
PE20070015A1 (en) 2007-02-06
RU2444520C2 (en) 2012-03-10
JP5118024B2 (en) 2013-01-16
KR20130118394A (en) 2013-10-29
NZ563740A (en) 2011-03-31
US8124763B2 (en) 2012-02-28
HK1117524A1 (en) 2009-01-16
TW200726756A (en) 2007-07-16
NO340743B1 (en) 2017-06-12
MX2007015423A (en) 2008-02-21
IL187421A0 (en) 2008-02-09
TNSN07463A1 (en) 2009-03-17
WO2006135641A3 (en) 2007-03-29
KR20120066067A (en) 2012-06-21
JO2636B1 (en) 2012-06-17

Similar Documents

Publication Publication Date Title
US8946416B2 (en) Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
CA2036304C (en) Pyrimidinedione derivatives, their production and use
EP1945627A1 (en) Pyrimidine derivatives for the treatment of cancer
EP0470795A1 (en) Process for the manufacture of nitriles
CN112920167A (en) Double-target inhibitor targeting FGFR and HDAC, preparation method and application thereof, pharmaceutical composition and medicament
EP2025665B1 (en) Process for producing substituted aniline compound
CN117203200A (en) Preparation method of xanthine oxidase inhibitor
CN101184748B (en) Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
WO2010018895A1 (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
HK1117524B (en) Process for the syntesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine
JP3161690B2 (en) Method for producing 2-mercaptoimidazole fused ring compound
CN112341344B (en) Preparation method of kinase inhibitor intermediate
JPH08231514A (en) Phenylbenzimidazole derivative
CN120004811A (en) Novel method for synthesizing 2-hydrazino-substituted pyrimidine
KR100539725B1 (en) New alkylation of pyrrole compound
JP2005126389A (en) Process for producing 2,4-dichloro-5-fluoropyrimidine
JPH1112254A (en) Method for producing 3- (3-pyridylmethylamino) -3,4-dihydro-2 (1H) -quinazolinone derivative and intermediate thereof
JPH0632782A (en) Pyrazole derivative and method for producing the same and medicine containing the same
JP2001278864A (en) Method for producing 4-methoxyquinolines
HK1140486A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680018425.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006772448

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12007502509

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 187421

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 8895/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 563740

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 11915671

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2610105

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006258051

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015423

Country of ref document: MX

Ref document number: 07129347

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020077028638

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008515881

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006258051

Country of ref document: AU

Date of ref document: 20060607

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2008000007

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007148231

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0611663

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020127011980

Country of ref document: KR